Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Disparities in work status after treatment for breast cancer: A controlled, longitudinal study
    Meeting Abstract

    Blinder, V. S.; Patil, S.; Eberle, C.; Jung, G.; Kampel, L. J.; Hwang, C.; Bao, T.; Robson, M. E.; Malik, M.; Gany, F.
    Cancer Epidemiology Biomarkers and Prevention (2020)

    Fulltext@MSK | Save
  • A pan-cancer analysis of double PIK3CA mutations
    Meeting Abstract

    Vasan, N.; Sivakumar, S.; Jin, D.; Ross, J. S.; Cantley, L. C.; Scaltriti, M.; Sokol, E. S.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab plus chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009
    Meeting Abstract

    Rugo, H. S.; Llombart Cussac, A.; AndreĢ, F.; Robson, M.; Saji, S.; Harbeck, N.; Schmid, P.; Cescon, D. W.; Seok Ahn, J.; Nanda, R.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • International phase III trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2-negative, locally recurrent or metastatic breast cancer (FORTRESS)
    Meeting Abstract

    Kaufman, P. A.; Martin, M.; Mayer, I.; Vahdat, L. T.; Pernas Simon, S.; Schmid, P.; McArthur, H. L.; Dent, R.; Rugo, H. S.; Barrios, C.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2-positive (HER2+) advanced breast cancer (ABC)
    Meeting Abstract

    Hurvitz, S. A.; Chia, S. K. L.; Ciruelos, E. M.; Hu, X.; Im, S. A.; Janni, W.; Jerusalem, G.; Lacouture, M.; O'Regan, R.; Rugo, H. S.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally advanced or metastatic HER2+ breast cancer
    Meeting Abstract

    Hurvitz, S. A.; Vahdat, L. T.; Harbeck, N.; Wolff, A. C.; Tolaney, S. M.; Loi, S.; Masuda, N.; O'Shaughnessy, J.; Dong, C.; Walker, L.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2- LA/MBC)
    Meeting Abstract

    Turner, N.; Jhaveri, K.; Kalinsky, K.; Loibl, S.; Loi, S.; Im, S. A.; Saura, C.; Schmid, P.; Schutzman, J. L.; Stout, T.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies
    Meeting Abstract

    Powell, C. A.; Camidge, D. R.; Modi, S.; Qin, A.; Taitt, C.; Lee, C.; Hackshaw, M. D.; Singh, J.; Iwata, H.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2- BC)
    Meeting Abstract

    Gambardella, V.; Cervantes, A.; Bedard, P. L.; Hamilton, E. P.; Italiano, A.; Jhaveri, K.; Juric, D.; Kalinsky, K.; Krop, I. E.; Oliveira, M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • A phase III trial of capivasertib and fulvestrant versus placebo and fulvestrant in patients with HR+/HER2- breast cancer (CAPItello-291)
    Meeting Abstract

    Turner, N.; Howell, S.; Jhaveri, K.; Gomez, H.; Toi, M.; Hu, X.; Loibl, S.; Rugo, H. S.; Ni, P.; De Bruin, E.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save